The World Health Organization (WHO) has approved two additional versions of the AstraZeneca/University of Oxford Covid-19 vaccine for emergency use. The vaccines in question are being produced by AstraZeneca-SKBio in South Korea and the Serum Institute of India. This approval allows the vaccines to be rolled out globally with the help of the COVAX facility.

According to reports by RIA news agency, India is likely to approve Russia’s Sputnik V vaccine to tackle Covid-19. The Russian vaccine candidate is currently being tested for safety and efficacy in small human trials being conducted in India. India’s Dr Reddy’s Laboratories and the Russian Direct Investment Fund (RDIF) have been collaborating to conduct these trials.

Novavax and SK Bioscience have expanded their  collaboration and license agreement for 40 million doses of the former’s Covid-19 vaccine in South Korea. In addition, SK Bioscience has obtained a license to increase the production capacity and supply to the South Korean government.

According to the German biotech firm Leukocare, a pan-European consortium  developing a Covid-19 vaccine is currently in discussion with big pharma to receive support for late-stage development of the jab and also to ramp up manufacturing. Leukocare has collaborated with Italy’s ReiThera and Belgium’s Univercells on an adenovirus vaccine candidate, which is similar to Covid-19 vaccines being developed by AstraZeneca/Oxford and Johnson & Johnson.



How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.